Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: Results of a markov model analysis

Clinical Therapeutics

Volumn 31, Issue SUPPL. 1, 2009, Pages 1456-1468

  Fajutrao, Liberty ^a   Paulsson, Björn ^a   Liu, Sherry ^b   Locklear, Julie ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

bipolar; cost effectiveness; lithium; maintenance; Markov model; quetiapine; valproate

Indexed keywords

LITHIUM SALT; PLACEBO; QUETIAPINE; VALPROIC ACID;

ADJUVANT THERAPY; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HIDDEN MARKOV MODEL; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MANIA; MENTAL HEALTH; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

AFFECT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FLUOXETINE; HEALTH STATUS; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALPROIC ACID;

EID: 68749095266     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.009     Document Type: Article

References (33)

1. Müller-Oerlinghausen B., Berghöfer A., and Bauer M. Bipolar disorder. Lancet 359 (2002) 241-247
2. Sajatovic M. Bipolar disorder: Disease burden. Am J Manag Care. 11 Suppl (2005) S80-S84
3. Dean B.B., Gerner D., and Gerner R.H. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 20 (2004) 139-154
4. Paykel E.S., Abbott R., Morriss R., et al. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry 189 (2006) 118-123
5. Altamura A.C., and Goikolea J.M. Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder. Neuropsychiatr Dis Treat. 4 (2008) 311-317
6. Goodwin F.K. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 63 Suppl 10 (2002) 5-12
7. Goodwin G.M., and Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17 (2003) 149-173 discussion
8. Goodwin G.M., and Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17 (2003) 147
9. Perlis R.H. Treatment of bipolar disorder: The evolving role of atypical antipsychotics [published correction appears in Am J Manag Care. 2008;14:76]. Am J Manag Care. 13 Suppl (2007) S178-S188
10. McIntyre R.S., Brecher M., Paulsson B., et al. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15 (2005) 573-585
11. Bowden C.L., Grunze H., Mullen J., et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66 (2005) 111-121
12. Calabrese J.R., Keck Jr. P.E., Macfadden W., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162 (2005) 1351-1360
13. Thase M.E., Macfadden W., Weisler R.H., et al., the BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study) [published correction appears in J Clin Psychopharmacol. 2007;27:51]. J Clin Psychopharmacol. 26 (2006) 600-609
14. Vieta E., Suppes T., Eggens I., et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 109 (2008) 251-263
15. Suppes T., Vieta E., Liu S., et al. Maintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry 166 (2009) 476-488
16. National Collaborating Centre for Mental Health. Bipolar Disorder. The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care (2006), Alden Press, Witney, UK
17. Soares-Weiser K., Bravo Vergel Y., Beynon S., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 11 (2007) iii-iv
18. Soares-Weiser K., Bravo Vergel Y., Beynon S., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 11 (2007) ix-206
19. Brecher M., Liu S., and Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term, phase III studies. Poster presented at: 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi and Agra, India (January 27-30, 2008)
20. Hospital Episode Statistics. England: Financial Year 2003-2004 (2004), Department of Health, London, UK
21. McKendrick J., Cerri K.H., Lloyd A., et al. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 21 (2007) 588-596
22. Briggs A., Claxton K., and Sculpher M. Decision Modelling for Health Economic Evaluation (2006), Oxford University Press, Oxford, UK
23. Joint Formulary Committee. British National Formulary. 51st ed (2006), British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK
24. UK Office for National Statistics 2007. http://www.statistics.gov.uk Accessed March 5, 2008
25. Guide to the Methods of Technology Appraisal (2006), National Institute for Health and Clinical Excellence, London, UK
26. Calvert N.W., Burch S.P., Fu A.Z., et al. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm. 12 (2006) 322-330
27. Brazier J., Roberts J., and Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 21 (2002) 271-292
28. Bowden C.L., Calabrese J.R., Sachs G., et al., Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder [published correction appears in Arch Gen Psychiatry. 2004;61:680]. Arch Gen Psychiatry 60 (2003) 392-400
29. Calabrese J.R., Bowden C.L., Sachs G., et al., the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64 (2003) 1013-1024
30. Tohen M., Bowden C.L., Calabrese J.R., et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomised double-blind placebo-controlled 12-month clinical trial. Bipolar Disord. 6 Suppl 1 (2004) 26
31. Tohen M., Calabrese J.R., Sachs G.S., et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163 (2006) 247-256
32. Devlin N., and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13 (2004) 437-452
33. Das Gupta R., and Guest J.F. Annual cost of bipolar disorder to UK society. Br J Psychiatry 180 (2002) 227-233